Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

CryoCath Technologies (CYT.TO)

WAIT
Good management. Have a better surgical procedure. People are starting to be convinced that it is better. Could be approaching the hockey stick growth curve. Wait for confirmation that revenues are accelerating.
WEAK BUY
In a transition area. Pretty good product. Think they've turned a corner and should have a good year.
DON'T BUY
Have very good technology. Earnings improved from minus .96 cents to minus.41 cents. Stock ranks in the bottom 10% of the database.
PAST TOP PICK
(Top pick Aug 13/03. Down 25%.) Saw a very large shareholder sell which drove down the stock price. That has to be digested. Should see revenues ramping up and new product approvals happening. Good technology.
TOP PICK
Focused on cardiovascular and intro fibrillation market.Should see sales ramp up this year.A very rapidly growing space.There is a potential for a take out.
DON'T BUY
A very good company. Starting to get massive approval. Would like to see better traction on revenues. Voatile.
BUY
If you like biotechs, this could be OK. Speculative.
DON'T BUY
A little bit suspect on the company at this time.
Showing 16 to 23 of 23 entries